Proleukin

DRUG12 trials

Sponsors

Cellectis, Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL, Vall D Hebron Institute Of Oncology, University of Minnesota, Assistance Publique - Hôpitaux de Paris

Conditions

Advanced selected solid tumors: melanomaAdvanced solid tumorsAlzheimer DiseaseCancerCryoglobulinemia VasculitisEncephalitisHIV InfectionIschemic Heart Disease

Phase 1

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

CompletedNCT00574652

French National Agency for Research on AIDS and Viral HepatitisCryoglobulinemia Vasculitis

Start: 2008-03-31End: 2010-09-30Updated: 2013-01-24

IL-2 in Refractory Autoimmune Encephalitis

CompletedNCT02714959

Seoul National University HospitalEncephalitis

Start: 2016-03-31End: 2019-06-12Updated: 2021-09-29

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

CompletedNCT03113773

Cambridge University Hospitals NHS Foundation TrustIschemic Heart Disease

Start: 2017-05-11End: 2019-02-21Updated: 2021-09-14

Adoptive Cell Therapy Across Cancer Diagnoses

CompletedNCT03296137

Inge Marie SvaneCancer

Start: 2017-10-13End: 2020-07-01Updated: 2024-10-26

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingCTIS2022-501607-27-00

CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma

Start: 2026-01-06Target: 48Updated: 2026-01-08

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

RecruitingNCT06204991

Inge Marie SvaneMelanoma, Melanoma Stage III, Melanoma Stage IV

Start: 2025-04-01End: 2028-04-01Target: 10Updated: 2025-08-24

Phase 2

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Sheba Medical CenterMetastatic Urothelial Carcinoma

Start: 2020-05-12End: 2023-06-01Target: 20Updated: 2021-02-11

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

RecruitingNCT05468073

Centre Hospitalier St AnneAlzheimer Disease

Start: 2022-10-11End: 2026-09-01Target: 45Updated: 2024-06-12

A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study

RecruitingCTIS2023-504632-17-00

Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELLAdvanced solid tumors

Start: 2024-08-14Target: 11Updated: 2025-08-19

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

RecruitingCTIS2023-506400-99-00

Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

Start: 2025-01-15Target: 24Updated: 2025-12-02

Phase 3

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

CompletedNCT00013611

University of MinnesotaHIV Infection

Start: 2001-03-31End: 2007-01-31Updated: 2011-08-08

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2

Assistance Publique - Hôpitaux de ParisLeukemia

Start: 2005-03-31End: 2012-03-31Target: 580Updated: 2009-02-12

Related Papers

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

Future Oncology2024-08-12

A phase 2, multicenter study of TILs treatment in advanced tumors with alterations in the SWI/SNF complex: The TILTS study.

Journal of Clinical Oncology2024-06-01

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Journal for ImmunoTherapy of Cancer2023-05-0131 citations

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease

NEJM Evidence2021-12-2259 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS)

European Heart Journal2020-11-018 citations

Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.

2020-07-0836 citations

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

BMJ Open2018-09-01109 citations

Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

Blood2016-12-021 citations

Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation

Journal of the American Heart Association2014-05-22219 citations

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

2011-12-01594 citations

Interleukin-2 therapy in patients with HIV infection.

2009-10-01295 citations